A Study of XYOSTED® for Testosterone Replacement in Male Adolescents With Conditions Associated with Deficiency or Absence of Endogenous Test

[madman]

https://www.bcm.edu/healthcare/clinical-trials/h-56187

Description

An Open-Label Multiple-Dose, 52-Week Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents (ages: 12 to <18 years) With Conditions Associated with Deficiency or Absence of Endogenous Testosterone Due to Primary or Secondary Hypogonadism (Congenital or Acquired)

Phase 3/4, open-label, multicenter study in approximately 100 males 12 to <18 years of age with primary or secondary hypogonadism (congenital or acquired)

 

[madman]

Thread 'XYOSTED Brand Refresh & Patient Experience'

Jun 2, 2025

XYOSTED Brand Refresh & Patient Experience

Working in collaboration with our global client portfolio to develop unique communications that affect meaningful change.

wearetmc.com

Supporting an established biopharmaceutical organisation, to ensure their groundbreaking Testosterone Replacement Therapy (TRT) stands out in a crowded market place.

Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies.

The organisation develops unique proprietary technology—and offers the first and only TRT weekly auto-injector of its kind; ‘XYOSTED’...

• madman
• hypogonadism; sub-q/xyosted; t-therapy
• Replies: 10
• Forum: Testosterone and Men's Health Articles